Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with …

RD Lopes, AVS Macedo, RJ Moll-Bernardes… - American Heart …, 2020 - Elsevier
Background Angiotensin-converting enzyme-2 (ACE2) expression may increase due to
upregulation in patients using angiotensin-converting enzyme inhibitors (ACEI) and …
被引用次数：142 相关文章

Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: impact on adverse outcomes in hospitalized patients with …

RD Lopes, AVS Macedo, PGM de Barros e Silva… - 2020 - cabidigitallibrary.org
Abstract Background: Angiotensin-converting enzyme-2 (ACE2) expression may increase
due to upregulation in patients using angiotensin-converting enzyme inhibitors (ACEI) and …

Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with …

RD Lopes, AVS Macedo… - American heart …, 2020 - pubmed.ncbi.nlm.nih.gov
Angiotensin-converting enzyme-2 (ACE2) expression may increase due to upregulation in
patients using angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor …
[HTML] nih.gov

[HTML][HTML] Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized …

RD Lopes, AVS Macedo, RJ Moll-Bernardes… - American Heart …, 2020 - ncbi.nlm.nih.gov
Background Angiotensin-converting enzyme-2 (ACE2) expression may increase due to
upregulation in patients using angiotensin-converting enzyme inhibitors (ACEI) and …

Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with …

RD Lopes, AVS Macedo, PGMB Silva… - 2020 - arca.fiocruz.br
Abstract Angiotensin-converting enzyme-2 (ACE2) may increase due to upregulation in
patients using angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor …

Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with …

RD Lopes, AVS Macedo, ESPGM de Barros… - American Heart …, 2020 - europepmc.org
Background Angiotensin-converting enzyme-2 (ACE2) expression may increase due to
upregulation in patients using angiotensin-converting enzyme inhibitors (ACEI) and …

[引用][C] Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized …

RD Lopes, AVS Macedo - American Heart Journal, 2020 - cir.nii.ac.jp
Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute …

Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with …

RD Lopes, AVS Macedo, PGM de Barros E Silva… - 2020 - dukespace.lib.duke.edu
Background: Angiotensin-converting enzyme-2 (ACE2) may increase due to upregulation in
patients using angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor …

[引用][C] Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized …

RD Lopes, AVS Macedo, PGMB Silva… - 2020 - pesquisa.bvsalud.org
Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute …

Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with …

RD Lopes, AVS Macedo, PGM de Barros E Silva… - 2020 - dukespace.lib.duke.edu
Abstract Angiotensin-converting enzyme-2 (ACE2) expression may increase due to
upregulation in patients using angiotensin-converting enzyme inhibitors (ACEI) and …